Navigation Links
Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Date:3/4/2008

AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals today announced that they have commenced the dosing of healthy subjects in a Phase I study of AFN-1252, one of its lead clinical candidates from its novel class of fatty acid biosyntheis inhibitors. The study of AFN-1252 will evaluate the safety, tolerability and pharmacokinetics of a single escalating oral dose. Affinium believes that AFN-1252 will provide patients and their doctors a potent, oral and IV treatment for susceptible and resistant staphylococcal infections both in and out of hospitals.

AFN-1252 is an investigational antibiotic, with a novel mechanism of action, and very high potency against all drug-resistant phenotpyes of staphylococci including hospital and community-acquired MRSA. Oral bioavailability has previously been demonstrated in a human microdosing study and excellent in vivo efficacy has been demonstrated in various animal models of infection.

"Affinium is very pleased to advance this novel class of antibiotics with great potential to address the serious unmet medical need for new oral and IV antibiotics capable of treating multi-drug resistant staphylococcal infections," said Dr. Barry Hafkin, Chief Medical Officer of Affinium Pharmaceuticals. "In preclinical studies, AFN-1252 was well tolerated at high multiples of the projected human dose in two species, suggesting a safety profile that would be very attractive to physicians practicing both in and out of hospital settings." Dr. Hafkin added that "the specific-spectrum of activity of AFN-1252 may provide further safety advantages by decreasing the risk of gut and cutaneous flora disruption."

About Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty ac
'/>"/>

SOURCE Affinium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
3. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
4. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
5. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
6. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
7. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
8. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
9. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
10. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
11. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PA (PRWEB) March 04, 2015 Cook ... non-profit organization that teaches healthy cooking to people touched ... AstraZeneca Hope Lodge. The program, run by founder Ann ... Hospitality and Sport Management. The unique partnership will expand ... Ann Ogden founded CFYL in 2007. After going through ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... Optrix by Body Glove ” was featured on NewsWatch ... a look at the latest and coolest technology products ... reporter for NewsWatch and a technology expert, conducted the ... an ultra-rugged, waterproof case with an interchangeable lens system. ... the Consumer Electronics Show in Las Vegas every year. ...
(Date:3/4/2015)... The popular all-natural supplement brand, Liporidex ... Program. The customized program provides a tailored diet and ... and fitness levels to follow and achieve their weight ... , “We’re really proud to announce our new program ... winning techniques to help people according to their specific ...
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3
... 7 (HealthDay News) -- In November, the U.S. Food and ... the treatment of breast cancer. But, a new study ... with a specific type of aggressive breast tumor when used ... (bevacizumab) had been approved in the United States in 2008 ...
... the fierce national debate over a new federal law ... widely assumed that private health insurance can do a ... U.S. government. But a first-of-its-kind analysis of newly ... comes to infants covered by insurance. Among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) ... with low-risk prostate cancer, a new draft report released ... concluded that research on the safety of "active surveillance" ... men opt for surgery or other treatments that can ...
... have altered natural bioelectrical communication among cells to directly ... at a particular location within a vertebrate organism. Using ... biologists at Tufts University,s School of Arts and Sciences ... of the head area. The researchers achieved most ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... through strategically placed "seeds" had double the risk of a ... their entire breast, new research finds. This type ... side effects, including infection, according to the study. "We ...
Cached Medicine News:Health News:Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study 2Health News:Public health insurance offers insured infants better, less costly care than private plans 2Health News:Public health insurance offers insured infants better, less costly care than private plans 3Health News:Public health insurance offers insured infants better, less costly care than private plans 4Health News:Public health insurance offers insured infants better, less costly care than private plans 5Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Targeted Radiation May Not Be Better for Breast Cancer 2Health News:Targeted Radiation May Not Be Better for Breast Cancer 3
(Date:3/4/2015)... 4, 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... present at the Barclays Global Healthcare Conference ... Miami Beach Hotel in Miami , ... M.D., President and Chief Executive Officer of Aratana Therapeutics, ...
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
(Date:3/4/2015)... -- Halyard Health, Inc. (NYSE: HYH ) today ... and related key planning assumptions. "This is ... our fourth quarter results, our first as an independent ... a smooth separation from Kimberly-Clark and I,m pleased with ... growth and margin improvement in the fourth quarter while ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31
... LAKE FOREST, Ill., March 5, 2012  RoundTable Healthcare ... exclusively on the healthcare industry, announced today that ... the newly formed RoundTable III Platform Development Corporation ... Mr. Davies will focus his attention on the ...
... 5, 2012   Synteract , Inc., a full-service contract research ... as senior vice president of sales and marketing and has ... global project management, to support growth in the company and ... COO Stewart Bieler, and CFO Patrik Jeanmonod on the executive ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: